TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

Eli Lilly-partnered TRexBio will apply the IPO proceeds towards medical growth of molecules designed to activate regulatory T cells to mediate immune responses and irritation. In the meantime, Retension Prescribed drugs will use its IPO money for mid-stage testing of a next-generation hypertension drug.

The publish TRrexBio’s IPO Baggage $116M to Carry the Immune System Again Into Steadiness appeared first on MedCity Information.

Source link